Keijiro Nozawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Keijiro Nozawa has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Keiji Matsuda
Teikyo University School of Medicine, Tokyo, Japan
11 shared publications - Toshiaki Watanabe
Center for Regenerative Medicine, National Center for Child Health and Development (NCCHD), Tokyo, Japan
11 shared publications - Ryu Shimada
Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo, 183-8605, Japan
9 shared publications Soichiro Ishihara
7 shared publicationsTamuro Hayama
7 shared publicationsHideki Yamada
6 shared publications
Latest Publications
- Open Access
- 2 July 2019
- Published by Springer Nature in BMC Surgery
- Vol. 19 (1) , 1-5
A case of intussusception developed at the site of ileocolic anastomosis after laparoscopic right hemicolectomy
Intussusception is a relatively common condition seen in children. In comparison, adult intussusception is rare and usually occurs as a complication in patients with organic diseases. It is responsible for 1% of all bowel obstructions, in most of intussusceptions a malignant tumor is involved. Herein, we present an extremely unusual case of intussusception that occurred as a complication at the site of a functional end-to-end anastomosis. A 57-year-old female patient was diagnosed with tumors in the ascending and descending colon and was referred to our department. Laparoscopic hemicolectomy and laparoscopic descending colectomy were performed. The mechanical intestinal obstruction occurred on the 9th day postoperatively, and computed tomography scan revealed intussusception at the site of the ileocolic anastomosis. Endoscopic reduction was attempted, but the procedure was challenging. Surgery was then performed and revealed that the site of ileocolic anastomosis firmly adhered to the side wall and right retroperitoneum. However, the intestine in the oral side of the anastomosis was not fixed. Examination of the anastomotic site revealed that the ileum had passed through the anastomosis and prolapsed into the transverse colon. The ileocolic anastomosis was resected. End-to-end anastomosis was performed, and surgery was then completed. No neoplastic lesions were observed in the resected tissue of the lead point of intussusception. The postoperative clinical course was favorable, and the patient was discharged on the 11th day after the second round of surgery. There are no reports the anastomosis is involved as part of the intussception, as observed in the present case. Intussusception should thus be considered as one of the causes of postoperative mechanical intestinal obstruction.
- 2 July 2019
- Published by Springer Nature in BMC Surgery
- Vol. 19 (1) , 1-5
Open AccessA case of intussusception developed at the site of ileocolic anastomosis after laparoscopic right hemicolectomy
Intussusception is a relatively common condition seen in children. In comparison, adult intussusception is rare and usually occurs as a complication in patients with organic diseases. It is responsible for 1% of all bowel obstructions, in most of intussusceptions a malignant tumor is involved. Herein, we present an extremely unusual case of intussusception that occurred as a complication at the site of a functional end-to-end anastomosis. A 57-year-old female patient was diagnosed with tumors in the ascending and descending colon and was referred to our department. Laparoscopic hemicolectomy and laparoscopic descending colectomy were performed. The mechanical intestinal obstruction occurred on the 9th day postoperatively, and computed tomography scan revealed intussusception at the site of the ileocolic anastomosis. Endoscopic reduction was attempted, but the procedure was challenging. Surgery was then performed and revealed that the site of ileocolic anastomosis firmly adhered to the side wall and right retroperitoneum. However, the intestine in the oral side of the anastomosis was not fixed. Examination of the anastomotic site revealed that the ileum had passed through the anastomosis and prolapsed into the transverse colon. The ileocolic anastomosis was resected. End-to-end anastomosis was performed, and surgery was then completed. No neoplastic lesions were observed in the resected tissue of the lead point of intussusception. The postoperative clinical course was favorable, and the patient was discharged on the 11th day after the second round of surgery. There are no reports the anastomosis is involved as part of the intussception, as observed in the present case. Intussusception should thus be considered as one of the causes of postoperative mechanical intestinal obstruction.
- Open Access
- 19 June 2018
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 16 (1) , 113
A rare case of perivascular epithelioid cell tumor (PEComa) of the greater omentum
A tumor composed exclusively or predominantly of human melanin black 45 (HMB45)-positive epithelioid cells is called a perivascular epithelioid cell tumor (PEComa). We report a very rare case of a PEComa of the greater omentum. MRI conducted to examine the orthopedic disease of the patients, a 49-year-old Japanese woman, also identified a tumor in her pelvis. A CT scan revealed a tumor mass on the right side of the pelvic floor and clear nutrient vessels originating from the splenic and celiac arteries. An omental primary tumor or accessory spleen was thus suspected, and tumor resection was performed. The tumor was a light brown solid tumor with a smooth margin, measuring 5.2 × 3.8 × 3.5 cm. Histopathologically, the tumor was composed mainly of spindle and epithelioid cells, and large and small blood vessel formation was observed. In the immunohistochemical staining, tumor cells were positive for human melanin black 45 (HMB-45) and Melan-A and partially positive for alpha-smooth muscle actin. The final diagnosis was PEComa of the greater omentum. Although omental PEComa is very rare, it should be considered as a differential disease of an omental primary tumor.
- 19 June 2018
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 16 (1) , 113
Open AccessA rare case of perivascular epithelioid cell tumor (PEComa) of the greater omentum
A tumor composed exclusively or predominantly of human melanin black 45 (HMB45)-positive epithelioid cells is called a perivascular epithelioid cell tumor (PEComa). We report a very rare case of a PEComa of the greater omentum. MRI conducted to examine the orthopedic disease of the patients, a 49-year-old Japanese woman, also identified a tumor in her pelvis. A CT scan revealed a tumor mass on the right side of the pelvic floor and clear nutrient vessels originating from the splenic and celiac arteries. An omental primary tumor or accessory spleen was thus suspected, and tumor resection was performed. The tumor was a light brown solid tumor with a smooth margin, measuring 5.2 × 3.8 × 3.5 cm. Histopathologically, the tumor was composed mainly of spindle and epithelioid cells, and large and small blood vessel formation was observed. In the immunohistochemical staining, tumor cells were positive for human melanin black 45 (HMB-45) and Melan-A and partially positive for alpha-smooth muscle actin. The final diagnosis was PEComa of the greater omentum. Although omental PEComa is very rare, it should be considered as a differential disease of an omental primary tumor.
- Open Access
- 1 January 2017
- Published by Open Access Text Pvt, Ltd. in Biomedical Research and Clinical Practice
- Vol. 2 (2)
Alteration of tumor markers may predict survival in colorectal cancer patients treated with TAS-102 or regorafenib as salvage-line chemotherapy: a single-institutional experience
- 1 January 2017
- Published by Open Access Text Pvt, Ltd. in Biomedical Research and Clinical Practice
- Vol. 2 (2)
Open AccessAlteration of tumor markers may predict survival in colorectal cancer patients treated with TAS-102 or regorafenib as salvage-line chemotherapy: a single-institutional experience
- 1 January 2016
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 69 (7) , 374-378
A Case of Colon Perforation Caused by Fecaloma of Barium after Upper Gastrointestinal Radiography
- 1 January 2016
- Published by Japan Society of Coloproctology in Nihon Daicho Komonbyo Gakkai Zasshi
- Vol. 69 (7) , 374-378
A Case of Colon Perforation Caused by Fecaloma of Barium after Upper Gastrointestinal Radiography
- Open Access
- 24 November 2015
- Published by Springer Nature in Surgical Case Reports
- Vol. 1 (1) , 118
A case of IgG4-related disease coexisted with rectal cancer
- 24 November 2015
- Published by Springer Nature in Surgical Case Reports
- Vol. 1 (1) , 118
Open AccessA case of IgG4-related disease coexisted with rectal cancer
- 1 June 2014
- Vol. 61 (132) , 1000-7
Number of Lymph Nodes in Rectal Cancer is Correlated with Response to Preoperative Chemoradiotherapy but is not Associated with Patient Survival.
We aimed to clarify the oncological significance of the number of lymph nodes in rectal cancers treated with preoperative chemoradiotherapy. We studied 126 curatively operated patients with clinical T3-T4 and M0 rectal cancers. The number of lymph nodes and clinicopathological features were compared between the patients treated with surgery alone (OP group, n = 45) and those treated with preoperative chemoradiotherapy (50-50.4 Gy in 25-28 fractions with tegafur-uracil and leucovorin, CRT group, n = 81). Factors influencing lymph node count and its prognostic significance were analyzed. The CRT group had significantly fewer lymph nodes than the OP group (12.4 vs. 21.1, P < 0.0001). High histological regression of rectal lesions was significantly correlated with decreased lymph node count in the CRT group. In the OP group, the 5-year cancer-specific survival rate of the patients with 12 or more lymph nodes was significantly better than those with fewer than 12 lymph nodes (75.1% vs. 33.3%, P = 0.02); in the CRT group, on the other hand, these survival rates did not differ (84.5% vs. 77.5%, P = 0.6). The number of lymph nodes in rectal cancer was correlated with the response of primary rectal lesions to chemoradiotherapy, and was not associated with patient survival.
- 1 June 2014
- Vol. 61 (132) , 1000-7
Number of Lymph Nodes in Rectal Cancer is Correlated with Response to Preoperative Chemoradiotherapy but is not Associated with Patient Survival.
We aimed to clarify the oncological significance of the number of lymph nodes in rectal cancers treated with preoperative chemoradiotherapy. We studied 126 curatively operated patients with clinical T3-T4 and M0 rectal cancers. The number of lymph nodes and clinicopathological features were compared between the patients treated with surgery alone (OP group, n = 45) and those treated with preoperative chemoradiotherapy (50-50.4 Gy in 25-28 fractions with tegafur-uracil and leucovorin, CRT group, n = 81). Factors influencing lymph node count and its prognostic significance were analyzed. The CRT group had significantly fewer lymph nodes than the OP group (12.4 vs. 21.1, P < 0.0001). High histological regression of rectal lesions was significantly correlated with decreased lymph node count in the CRT group. In the OP group, the 5-year cancer-specific survival rate of the patients with 12 or more lymph nodes was significantly better than those with fewer than 12 lymph nodes (75.1% vs. 33.3%, P = 0.02); in the CRT group, on the other hand, these survival rates did not differ (84.5% vs. 77.5%, P = 0.6). The number of lymph nodes in rectal cancer was correlated with the response of primary rectal lesions to chemoradiotherapy, and was not associated with patient survival.
- 1 January 2014
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 57 (1) , 23-31
Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Using Reverse Transcriptase Polymerase Chain Reaction Analysis of Four Genes
Patients with rectal cancer exhibit a wide spectrum of responses to chemoradiotherapy. Several gene expression signatures have been reported to predict the response to chemoradiotherapy in rectal cancer, but the lack of practical assays has restricted the clinical use of this technique. We aimed to identify a set of discriminating genes that can be used for the clinical prediction of response to chemoradiotherapy in rectal cancer. This study is a retrospective analysis of tumor samples in a single institute. Sixty-two patients who underwent preoperative chemoradiotherapy were studied. Gene expression was initially studied in 46 training samples by microarray analysis, and the association between gene expression and response to chemoradiotherapy was evaluated. Quantitative reverse transcriptase polymerase chain reaction was performed to validate the microarray expression levels of the discriminating genes. We developed a gene expression model for the prediction of response to chemoradiotherapy based on the reverse transcriptase polymerase chain reaction findings and validated it by using 16 independent test samples. We identified 24 discriminating probes with expression levels that differed significantly between responders and nonresponders. Among 18 genes identified by Gene Symbol, real-time reverse transcriptase polymerase chain reaction showed significant differences in the expression of 16 genes between responders and nonresponders. We constructed a predictive model by using different sets of these 16 genes, and the highest accuracy rate (89.1%) was obtained by using LRRIQ3, FRMD3, SAMD5, and TMC7. The predictive accuracy rate of this 4-gene signature in the independent set of 16 patients was 81.3%. Validation in a different and large cohort of patients is necessary. The 4-gene signature identified in this study is closely associated with response to chemoradiotherapy in rectal cancer.
- 1 January 2014
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 57 (1) , 23-31
Prediction of Response to Preoperative Chemoradiotherapy in Rectal Cancer by Using Reverse Transcriptase Polymerase Chain Reaction Analysis of Four Genes
Patients with rectal cancer exhibit a wide spectrum of responses to chemoradiotherapy. Several gene expression signatures have been reported to predict the response to chemoradiotherapy in rectal cancer, but the lack of practical assays has restricted the clinical use of this technique. We aimed to identify a set of discriminating genes that can be used for the clinical prediction of response to chemoradiotherapy in rectal cancer. This study is a retrospective analysis of tumor samples in a single institute. Sixty-two patients who underwent preoperative chemoradiotherapy were studied. Gene expression was initially studied in 46 training samples by microarray analysis, and the association between gene expression and response to chemoradiotherapy was evaluated. Quantitative reverse transcriptase polymerase chain reaction was performed to validate the microarray expression levels of the discriminating genes. We developed a gene expression model for the prediction of response to chemoradiotherapy based on the reverse transcriptase polymerase chain reaction findings and validated it by using 16 independent test samples. We identified 24 discriminating probes with expression levels that differed significantly between responders and nonresponders. Among 18 genes identified by Gene Symbol, real-time reverse transcriptase polymerase chain reaction showed significant differences in the expression of 16 genes between responders and nonresponders. We constructed a predictive model by using different sets of these 16 genes, and the highest accuracy rate (89.1%) was obtained by using LRRIQ3, FRMD3, SAMD5, and TMC7. The predictive accuracy rate of this 4-gene signature in the independent set of 16 patients was 81.3%. Validation in a different and large cohort of patients is necessary. The 4-gene signature identified in this study is closely associated with response to chemoradiotherapy in rectal cancer.
- 1 November 2012
- Vol. 39 (12) , 1763-5
[Usefulness of CTCs in tumor drainage vein blood as a biomarker for prognosis in colorectal cancer patients with Dukes' stage B and C].
We aimed to clarify the clinical significance of circulating tumor cells (CTCs) in the tumor drainage vein blood of colorectal cancer(CRC) patients with Dukes' stage B and C. This study included 111 patients with Dukes' stage B and 86 patients with Dukes' stage C. We selected multiple genetic markers, including the cancer-associated marker (CEA), epithelial markers(CK19 and CK20), and cancer stem-like cell marker(CD133), and the mRNA levels of these genes were detected by quantitative real-time reverse transcription-polymerase chain reaction assays. In Kaplan-Meier survival curve analysis, overall survival(OS) and disease-free survival(DFS) of Dukes' stage B and C patients who were positive for CEA, CK19, CK20, and/or CD133 (CEA/CK/CD133) were significantly worse than that in patients who were negative for these markers. By Cox progression analysis, it was demonstrated that CEA/CK/CD133 mRNA in tumor drainage vein blood was an independent prognostic factor for OS and DFS in these patients. These results suggest that CEA/CK/CD133 mRNA detection in tumor drainage vein blood is a useful tool for the determination of high-risk CRC patients with Dukes' stage B and C who are in need of postoperative adjuvant therapy.
- 1 November 2012
- Vol. 39 (12) , 1763-5
[Usefulness of CTCs in tumor drainage vein blood as a biomarker for prognosis in colorectal cancer patients with Dukes' stage B and C].
We aimed to clarify the clinical significance of circulating tumor cells (CTCs) in the tumor drainage vein blood of colorectal cancer(CRC) patients with Dukes' stage B and C. This study included 111 patients with Dukes' stage B and 86 patients with Dukes' stage C. We selected multiple genetic markers, including the cancer-associated marker (CEA), epithelial markers(CK19 and CK20), and cancer stem-like cell marker(CD133), and the mRNA levels of these genes were detected by quantitative real-time reverse transcription-polymerase chain reaction assays. In Kaplan-Meier survival curve analysis, overall survival(OS) and disease-free survival(DFS) of Dukes' stage B and C patients who were positive for CEA, CK19, CK20, and/or CD133 (CEA/CK/CD133) were significantly worse than that in patients who were negative for these markers. By Cox progression analysis, it was demonstrated that CEA/CK/CD133 mRNA in tumor drainage vein blood was an independent prognostic factor for OS and DFS in these patients. These results suggest that CEA/CK/CD133 mRNA detection in tumor drainage vein blood is a useful tool for the determination of high-risk CRC patients with Dukes' stage B and C who are in need of postoperative adjuvant therapy.
- 13 August 2011
- Vol. 58, 756-62
Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer.
Concomitant chemotherapy increases the therapeutic effect of preoperative radiotherapy for rectal cancer. The aim was to investigate the clinical benefit of tegafur-uracil (UFT) and leucovorin (LV) in preoperative chemoradiotherapy for rectal cancer. Patients who had undergone curative resections of rectal cancers following preoperative radiotherapy (50-50.4Gy) with UFT and LV (CRT group: n=30) or radiotherapy without chemotherapy (RT group: n=33) were studied. Clinical outcomes were compared between both groups. Responders to preoperative therapy (>66% pathological resolution of their cancer) comprised 56.7% and 36.4% of the CRT and RT groups, respectively. Complete response was observed in 10.0% and in 6.1% of the CRT and RT groups, respectively. Pathological lymph node metastasis was positive in 10.0% and in 39.4% of the CRT and RT groups, respectively (p=0.0001). Sphincter-preserving surgery was performed in more patients in the CRT group than in the RT group (63.3% vs. 36.4%, p=0.04). Anastomotic leakage or pelvic abscess was seen in 6.7% and 27.3% of the CRT and RT groups, respectively. Anal function, estimated by the frequency of defecation and the Wexner incontinence score, was equally fair in both groups. Administration of UFT and LV enhanced the pathological response to preoperative radiotherapy, especially that of lymph node metastasis, and increased the frequency of sphincter-preserving surgery without compromising postoperative course.
- 13 August 2011
- Vol. 58, 756-62
Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer.
Concomitant chemotherapy increases the therapeutic effect of preoperative radiotherapy for rectal cancer. The aim was to investigate the clinical benefit of tegafur-uracil (UFT) and leucovorin (LV) in preoperative chemoradiotherapy for rectal cancer. Patients who had undergone curative resections of rectal cancers following preoperative radiotherapy (50-50.4Gy) with UFT and LV (CRT group: n=30) or radiotherapy without chemotherapy (RT group: n=33) were studied. Clinical outcomes were compared between both groups. Responders to preoperative therapy (>66% pathological resolution of their cancer) comprised 56.7% and 36.4% of the CRT and RT groups, respectively. Complete response was observed in 10.0% and in 6.1% of the CRT and RT groups, respectively. Pathological lymph node metastasis was positive in 10.0% and in 39.4% of the CRT and RT groups, respectively (p=0.0001). Sphincter-preserving surgery was performed in more patients in the CRT group than in the RT group (63.3% vs. 36.4%, p=0.04). Anastomotic leakage or pelvic abscess was seen in 6.7% and 27.3% of the CRT and RT groups, respectively. Anal function, estimated by the frequency of defecation and the Wexner incontinence score, was equally fair in both groups. Administration of UFT and LV enhanced the pathological response to preoperative radiotherapy, especially that of lymph node metastasis, and increased the frequency of sphincter-preserving surgery without compromising postoperative course.
- 20 July 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (21) , 2947-2948
Reply to B. Faltas et al
- 20 July 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (21) , 2947-2948
Reply to B. Faltas et al